GRIP Molecular Technologies and Molecular Testing Labs (MTL) have announced a collaboration, which involved a successful clinical feasibility study of an advanced electronic biosensor technology.
The aim is to deliver lab-quality, multi-disease diagnostic test results directly to consumers within minutes.
Go deeper with GlobalData
The disposable diagnostic cartridge of GRIP utilises samples collected by the user and deploys a standard smartphone to show test results and sends them to the user’s clinician, facilitating data-informed telehealth interaction.
This allows for the rapid diagnosis of diseases and the prompt administration of suitable therapy through a virtual platform.
MTL co-founder and chief innovation officer Adam Blackwell said: “Our collaboration with GRIP is a testament to our shared commitment to empower consumers by providing them ready access to their health information.
“Together, we are committed to developing and offering new technologies that improve health, enhance healthcare experiences, and reduce costs in ways not possible with currently commercialised technologies.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe GRIP biosensor sends data wirelessly to a standard cell phone or other mobile device for display. It helps avoid the use of electric cables or separate readers.
Test results can be sent to a healthcare provider securely, enabling virtual telehealth or in-person clinic consultations.
GRIP founder and chief technology officer Bruce Batten said: “Using MTL’s highly characterised infected patient nasal swab samples, we have bolstered prior evidence of the GRIP technology’s extraordinary performance capabilities, with combined levels of diagnostic speed, convenience, and accuracy not possible with alternative technologies available for home use.
“Evidence shows the prompt application of appropriate therapy is important to maximise its beneficial impact — and typically this is within 48 hours of symptom onset when many home-based diagnostics provide concerningly low levels of accuracy, leading to diagnosis delays.”
